Adaptive
Seattle, United States · 50 employees
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from ful
Funding history
- Series seed — $7.0M — Apr 2025
- Series series a — $19.0M — Jul 2024
Recent signals
- Apr 22, 2025: Raised $7.0M in Series seed
- Feb 04, 2025: Adaptive and Rapid Addition Announce Partnership for Best-in-class FIX Capabilities
- Jul 15, 2024: Raised $19.0M in Series series a
See plans & pricing → Track Adaptive’s funding, hiring, and signals — with verified contacts — on Fundz.